²Ä 2385´Á

113 / 10. 28~ 11. 3

¾Ç²ß

Á{§ÉÃľǥæ¬y
·s´ڱaª¬¯p¯l¬Ì­]±µºØ¶¡¹j

¡@




¡·¤å¡þ¶ÀÄÉùÜÃÄ®v

¯f¤H°Ý¡G¦pªG±µºØ¹L±aª¬¯p¯l¬Ì­]¡]¥ñ±a¯l, Zostavax¡^¡AÁÙ¥i¥H¦A¥´·sªº±aª¬¯p¯l¬Ì­]¡]ªY«g¯l, Shingrix¡^¶Ü¡H»Ý­n¶¡¹j¦h¤[¡H


ÃÄ®vµª¡G¥i¥H¡C¦Ü¤Ö¶¡¹j2­Ó¤ë¡C


ÃÄ®v¸Óª¾¹Dªº¨Æ


±aª¬¯p¯l©Î«UºÙ¥Ö³D¡A¬O¤@ºØ·|³y¦¨±j¯P¯kµhªº¥Ö½§¯l¡A³q±`µo¥Í¦bÁy³¡©Î¨­Å骺¤@°¼¡C¥¦¥Ñ¤ôµk-±aª¬¯p¯l¯f¬r¡]varicella-zoster virus, VZV¡^¤Þ°_¡A³oºØ¯f¬r¤]¬O¤Þ°_¤ôµkªº­ì¦]¡C¥ô¦ó±o¹L¤ôµkªº¤H³£¥i¯àµo¥Í±aª¬¯p¯l¡A¦]¬°VZV¦b¤ôµk±d´_«á¤´µM¯d¦bÅ餺¡CVZV¦b¦~ªø¦¨¤H¡B§K¬Ì¥\¯à¤£¥þªº¯f¤H¡A¥H¤ÎªA¥Î§í¨î§K¬Ì¨t²ÎÃĪ«ªº¤H¸s¤¤®e©ö­«·s¬¡¤Æ¡A¾É­P±aª¬¯p¯l¡C±µºØ¬Ì­]¬O¹w¨¾±aª¬¯p¯lªº³Ì¨Î¤è¦¡¡C


·s´Úªº±aª¬¯p¯l¬Ì­]¡]ªY«g¯l, Shingrix¡^»Ý­n¬I¥´¨â¾¯¡]²Ä0, 2-6­Ó¤ë¡^¡A¬°¤@ºØ«D¬¡©Ê°ò¦]­«²Õ¬Ì­]¡]Recombinant Zoster Vaccine, RZV¡^¡A¦b¤@¶µphase III¡B¦h¤¤¤ßªº¬ã¨s¦¬¯Ç¶W¹L30,000¤H¡A¥HÀH¾÷1¡G1¤À°tµ¹¤©¬Ì­]©ÎªÌ¦w¼¢¾¯¡A¨Ã°õ¦æ¨â¶¥¬qµû¦ô®Ä¤O»P¦w¥þ©Ê¡Cµ²ªGÅã¥Ü¡A¹w¨¾±aª¬¯p¯lªº®ÄªG¦b50¦Ü59·³¬°96.6%¡]95% CI= 89.6-99.3¡^¡B60¦Ü69·³¬°97.4%¡]95% CI = 90.1-99.7¡^¡B70·³¤Î¥H¤W¬°91.3%¡]95% CI = 86.8-94.5¡^¡C¹w¨¾±aª¬¯p¯l«á¯«¸gµhªº®ÄªG¦b50·³¤Î¥H¤W¬°91.2%¡]95% CI = 75.9-97.7¡^¡A70·³¤Î¥H¤WªÌ¤¤¬°88.8%¡]95% CI = 68.7-97.1¡^¡C³Ì±`¨£ªº°Æ§@¥Î¬°¯kµh¡]78%¡^¡B¦Ù¦×µh¡]45%¡^©M¯h³Ò¡]45%¡^¡C


´ڪº±aª¬¯p¯l¬Ì­]¡]¥ñ±a¯l, Zostavax¡^¡A¬O¤@ºØ¬¡©Ê´î¬r¬Ì­]¡]Zoster Vaccine Live ,ZVL¡^¡A¥u»Ý­n¥´¤@¾¯¡C¦b¨â¶µÀH¾÷¹ï·Ó¸ÕÅç»P¤C¶µÆ[¹î©Ê¬ã¨s¤¤¡A¨ä¹w¨¾±aª¬¯p¯lªº®ÄªG¦b50¦Ü59·³¬°70%¡]95% CI = 54-81¡^¡B60¦Ü69·³¬°64%¡]95% CI = 56-71¡^¡B70·³¤Î¥H¤W¬°38%¡]95% CI = 25-48¡^¡A¥B®Ä¤OÀHµÛ±µºØ®É¶¡¹L±o¶V¤[­°§C¶V¦h¡C¹w¨¾±aª¬¯p¯l«á¯«¸gµhªº®ÄªG¦b60¦Ü69·³65.7%¡]95% CI = 20.4-86.7¡^¡B70·³¤Î¥H¤W¬°66.8%¡]95% CI = 43.3-81.3¡^¡C
¦]Shingrix¦b¹w¨¾±aª¬¯p¯lªº®Ä¤O©úÅãÀu©ó Zostavax¡A¥Ø«e¬ü°ê¬Ì­]±µºØ¿Ô¸ß©e­û·|¡]Advisory Committee on Immunization Practices, ACIP¡^«Øij­Y¥¼¥´¹L¥ô¦ó±aª¬¯p¯l¬Ì­]¡AÀu¥ý¿ï¾Ü¬I¥´Shingrix¡A¦pªG¤w¸g¥´¹LZostavax¡A¤´«Øij¦Aª`®gShingrix¡A¦Ü¤Ö»Ý¶¡¹j¨â­Ó¤ë¡C



°Ñ¦Ò¸ê®Æ¡G


1.Boutry C, Hastie A, Diez-Domingo J, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster¡G Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74¡]8¡^¡G1459-1467. doi¡G10.1093/cid/ciab629
2.Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54¡G922-8
3.Oxman MN, Levin MJ, Johnson GR, et al. ; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352¡G2271-84.
4.CDC- Frequently Asked Questions About Shingrix. https¡G//www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/faqs.html
¡@


¡]¥»¤å§@ªÌ¬°©_¬üÂåÀø°]¹Îªk¤H©_¬üÂå°|Á{§ÉÃÄ®v /¤¤°êÂåÃĤj¾ÇÃľǨt¾Ç¤h¡^

¡@

¡@

¡@

¡@

¡@

¡@

¦^­º­¶